Investigators Recruiting for Study of ALKS 8700 vs. Dimethyl Fumarate in Relapsing-Remitting MS

SUMMARY Investigators are recruiting 420 people with relapsing-remitting MS for a phase 3 study comparing gastrointestinal side effects experienced during treatment with oral ALKS 8700 (Alkermes, Inc.) or Tecfidera® (dimethyl fumarate, Biogen, Inc.). The study is funded by Alkermes, Inc. DETAILS Rationale: Multiple sclerosis occurs when the immune system mistakenly attacks nerve fiber-insulating myelin and other brain and spinal cord tissues. Although its exact mechanism of action is not known, oral dimethyl fumarate, which is approved to treat people with relapsing MS, is thought to inhibit immune cells and molecules…

Favicon of da :

Prosegui la lettura...
Traduci l'articolo...

Sclerosi Multipla News

Potrebbe interessarti anche

Argomenti correlati